Harvard
Pappot, H, Baeksted, C, Knoop, A, Mitchell, SA, Nissen, A
& Johansen, C 2019, '
Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE)'
Breast, bind 25, nr. 2, s. 269-272.
https://doi.org/10.1111/tbj.13204
APA
Pappot, H., Baeksted, C., Knoop, A., Mitchell, S. A., Nissen, A.
, & Johansen, C. (2019).
Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Breast,
25(2), 269-272.
https://doi.org/10.1111/tbj.13204
CBE
MLA
Vancouver
Author
Bibtex
@article{9a555e7b9162451f976964d1eb185639,
title = "Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE)",
abstract = "The Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute to capture patient self-reports of symptomatic toxicities during cancer treatment. The aim of this short communication is to describe the design of a national study, which examine the effect of using patients' electronic PRO-CTCAE reporting with real-time feedback to clinicians on treatment events for breast cancer patients receiving adjuvant chemotherapy. The study's end-points are defined as dose reduction, hospitalization, and febrile neutropenia. This is the first report on the impact of PRO-CTCAE in a national breast cancer population during chemotherapy treatment.",
keywords = "PRO-CTCAE, adjuvant chemotherapy, breast cancer, patient reported outcome, toxicity, Humans, Hospitalization, Neutropenia/chemically induced, Randomized Controlled Trials as Topic, Denmark, Female, Chemotherapy, Adjuvant/adverse effects, Breast Neoplasms/drug therapy, Patient Reported Outcome Measures",
author = "Helle Pappot and Christina Baeksted and Ann Knoop and Mitchell, {Sandra A} and Aase Nissen and Christoffer Johansen",
note = "{\circledC} 2019 Wiley Periodicals, Inc.",
year = "2019",
doi = "10.1111/tbj.13204",
language = "English",
volume = "25",
pages = "269--272",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "2",
}
RIS
TY - JOUR
T1 - Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE)
AU - Pappot, Helle
AU - Baeksted, Christina
AU - Knoop, Ann
AU - Mitchell, Sandra A
AU - Nissen, Aase
AU - Johansen, Christoffer
N1 - © 2019 Wiley Periodicals, Inc.
PY - 2019
Y1 - 2019
N2 - The Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute to capture patient self-reports of symptomatic toxicities during cancer treatment. The aim of this short communication is to describe the design of a national study, which examine the effect of using patients' electronic PRO-CTCAE reporting with real-time feedback to clinicians on treatment events for breast cancer patients receiving adjuvant chemotherapy. The study's end-points are defined as dose reduction, hospitalization, and febrile neutropenia. This is the first report on the impact of PRO-CTCAE in a national breast cancer population during chemotherapy treatment.
AB - The Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute to capture patient self-reports of symptomatic toxicities during cancer treatment. The aim of this short communication is to describe the design of a national study, which examine the effect of using patients' electronic PRO-CTCAE reporting with real-time feedback to clinicians on treatment events for breast cancer patients receiving adjuvant chemotherapy. The study's end-points are defined as dose reduction, hospitalization, and febrile neutropenia. This is the first report on the impact of PRO-CTCAE in a national breast cancer population during chemotherapy treatment.
KW - PRO-CTCAE
KW - adjuvant chemotherapy
KW - breast cancer
KW - patient reported outcome
KW - toxicity
KW - Humans
KW - Hospitalization
KW - Neutropenia/chemically induced
KW - Randomized Controlled Trials as Topic
KW - Denmark
KW - Female
KW - Chemotherapy, Adjuvant/adverse effects
KW - Breast Neoplasms/drug therapy
KW - Patient Reported Outcome Measures
U2 - 10.1111/tbj.13204
DO - 10.1111/tbj.13204
M3 - Journal article
VL - 25
SP - 269
EP - 272
JO - Breast
JF - Breast
SN - 0960-9776
IS - 2
ER -